Erector Spinae Catheter Versus Paravertebral Catheter for Postoperative Analgesia in Cancer Patients Post Mastectomies
NCT ID: NCT05771116
Last Updated: 2023-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
70 participants
INTERVENTIONAL
2023-01-01
2023-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
.70 patients will be included in this prospective randomized study. The patients will be allocated into two groups: the ESPB group (group E, n = 35) , and the paravertebral group (group P, n =35)
* All patients will do Ultrasound-guided ESPB for group E and PVB for group P before receiving general anesthesia
* Postoperatively Patients in both groups will receive intravenous morphine 3 mg as rescue analgesic
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Different Volumes Spread of Erector Spinae Block in Post Mastectomy Pain Syndrome Management
NCT05192278
Erector Spinae Block Versus PECS Block Type II for Breast Surgeries
NCT04284124
Comparison of Erector Spinae Plane Block With Serratus Anterior Plane Block for Breast Surgery
NCT03579524
Different Volumes of Erector Spinae Plane Block for Breast Surgery
NCT05232084
Ultrasound-guided Multilevel Erectorspinae Plane Block Versus Thoracic Epidural Analgesia for Prevention of Post Mastectomy Pain Syndrome for Breast Cancer Patients
NCT06884852
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* All patients will do Ultrasound-guided ESPB for group E and PVB for group P before receiving GA
* Postoperatively Patients in both groups will receive intravenous morphine 3 mg as rescue analgesic.
* Random numbers were generated using a computer-generated randomization code and were sealed in an opaque envelope. Randomization was conducted by a person who was not involved in the study.
* An independent observer who was blind to the group assignment checked the intraoperative and postoperative data.
* VAS pain score immediately postoperative and at 2,4,6, 8,12,18,24,36 ,48hrs.postoperative.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Erecto Spinae Plane Block group
a high-frequency linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T7 spinous process. This should reveal three muscles superficial to the hyperechoic transverse process shadow as follows: trapezius, rhomboid major, and erector spinae. The skin will be anaesthetized using 3ml of 2% Lidocaine. A 20-gauge block needle will be inserted in-plane in a cephalad-to-caudad direction to place the tip into the fascial plane on the deep (anterior) aspect of erector spinaemuscle;20ml bupivacaine 0.25% will be injected. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process The needle will be removed and the catheter secured with adhesive.
ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:
catheter will be placed for ERECTOR SPINAE PLANE BLOCK
PARAVERTEBRAL BLOCK:
catheter will be placed for PARAVERTEBRAL BLOCK
the paravertebral group
After identification of the transverse process, internal intercostal membrane (IIM), and pleura at the T3 and T6 levels, an out-of-plane needle guidance technique was used to perform the PVB.The success of both blocks will be confirmed by loss of pinprick sensation on the dermatomal site of the block
•blocks will be activated ,After negative aspiration, 0.5 ml/kg 0.25% bupivacaine (max 20 ml) will be injected. Afterwards, a 20 gauge peripheral nerve catheter will be easily threaded into the space. The needle will be removed and the catheter secured with adhesive.
ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:
catheter will be placed for ERECTOR SPINAE PLANE BLOCK
PARAVERTEBRAL BLOCK:
catheter will be placed for PARAVERTEBRAL BLOCK
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ERECTOR SPINAE PLANE BLOCK and PARAVERTEBRAL BLOCK:
catheter will be placed for ERECTOR SPINAE PLANE BLOCK
PARAVERTEBRAL BLOCK:
catheter will be placed for PARAVERTEBRAL BLOCK
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
. Patients (age 20-70yrs) scheduled for breast surgeries for breast cancer under general anesthesia
Exclusion Criteria
* Known sensitivity or contraindication to local anesthetics.
* Localized infection at the site of block.
* patients with coagulopathy or an (INR ≥ 2)
20 Years
70 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute, Egypt
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
suzan adlan, lecturer
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute, Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NCIEgypt
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AP2212-501-034
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.